Generic and biosimilar medicines created $467 billion in savings for patients and the overall healthcare system in 2024, according to The Association for Accessible Medicines’ 2024 U.S. Generic & Biosimilar Medicines Saving Report.
The report also noted that generics and biosimilars have saved more than $3.4 trillion in the last decade.
Despite the impressive savings, AAM president and CEO John Murphy III cautioned that generics and biosimilars are the only sector that consistently results in decreased spending across the U.S. healthcare ecosystem, but little is being done to infuse sustainability into the generic and biosimilar marketplace. Read More >
